Mass General Brigham & Massachusetts General Hospital, Endocrine Division
Sponsored by: Endocrine Unit
Endocrine Grand Rounds
Tuesday, April 18th 2023
Ether Dome *In-Person Event*
Hybrid Zoom option available for those unable to attend in person. Contact CSRmail@partners.org for Zoom information.
“Fibroblast Growth Factor 23, Osteomalacia, Hypophosphatemia and Osteoarthropathy: Lessons Learned from High Molecular Weight FGF2 Transgenic mice”
Marja Hurley, MD, FASBMR
UConn Board of Trustees Distinguished Professor
Professor of Medicine and Orthopaedic Surgery
Member Institute of Systems Genomics
Institutional Designee, AAMC, Group Women in Medicine and Science
Associate Dean Health Career Opportunity Programs
Founding Director, Aetna Health Professions Partnership Initiative
UCONN Health Schools of Medicine & Dental Medicine, Farmington, CT
Upon completion of this activity, participants will be able to:
- Have a broader understanding of the potential role of High molecular weight isoforms of fibroblast growth factor-2 (HMWFGF2) and Fibroblast Growth Factor receptors in rickets and osteoarthritis development in mice
- Speculate whether modulation of FGF2/FGF23/FGF receptor signaling affect osteomalcaia and osteoarthritis in mice
- Understand the potential role of HMWFGF2/FGF23 in genetic disorder XLH
Target Audience: This activity is intended for Endocrinologists and Health Care Professionals with an interest in Endocrine Topics
Course Director: Jose Florez, M.D., Ph.D.
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mass General Brigham designates this live activity for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.